Cisplatin resistance in germ cell tumours: Models and mechanisms

Andrology

Volumn 3, Issue 1, 2015, Pages 111-121

  Jacobsen, C ^a   Honecker, F ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Tumor and Breast Center ZeTuP St Gallen   (Switzerland)

Author keywords

Apoptosis; DNA damage; DNA repair; Testis cancer

Indexed keywords

AZACITIDINE; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CABAZITAXEL; CISPLATIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FAS ANTIGEN; FLAVOPIRIDOL; GEMCITABINE; IFOSFAMIDE; MICRORNA; MICRORNA 106B; MICRORNA 17; MICRORNA 302A; MICRORNA 371; MICRORNA 373; NUTLIN 3; OCTAMER TRANSCRIPTION FACTOR 4; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PROTEIN MDM2; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; RAPAMYCIN; RETINOIC ACID; UNCLASSIFIED DRUG; VINBLASTINE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DEMETHYLATION; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DOWN REGULATION; DRUG RESPONSE; EMBRYONAL CARCINOMA CELL LINE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; GERM CELL TUMOR; HOMOLOGOUS RECOMBINATION; HUMAN; LONG TERM SURVIVAL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; UPREGULATION; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TESTICULAR NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; SIGNAL TRANSDUCTION; TESTICULAR NEOPLASMS;

EID: 84923218693     PISSN: 20472919     EISSN: 20472927     Source Type: Journal    
DOI: 10.1111/andr.299     Document Type: Article

References (100)

1. Abada PB & Howell SB. (2014) Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells. PLoS ONE 9, e87444.
2. Bartkova J, Rajpert-De Meyts E, Skakkebaek NE, Lukas J & Bartek J. (2007) DNA damage response in human testes and testicular germ cell tumours: biology and implications for therapy. Int J Androl 30, 282-291; discussion 291.
3. Bassett E, Vaisman A, Tropea KA, McCall CM, Masutani C, Hanaoka F & Chaney SG. (2002) Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases beta and eta. DNA Repair (Amst) 1, 1003-1016.
4. Bauer S, Mühlenberg T, Leahy M, Hoiczyk M, Gauler T, Schuler M & Looijenga L. (2010) Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours. Eur Urol 57, 679-687.
5. Beer TM, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, Quinn DI, Raghavan D & Crawford ED. (2006) Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer 106, 2624-2629.
6. Berger LA, Bokemeyer C, Lorch A, Hentrich M, Kopp H-G, Gauler TC, Beyer J, de Wit M, Mayer F, Boehlke I, Oing C, Honecker F & Oechsle K. (2014) First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). J Cancer Res Clin Oncol 140, 1211-1220.
7. Beyer U, Moll-Rocek J, Moll UM & Dobbelstein M. (2011) Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes. Proc Natl Acad Sci USA 108, 3624-3629.
8. Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Claßen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germa-Lluch JR, Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LHJ, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C & Wittekind C. (2013) Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24, 878-888.
9. Beyrouthy MJ, Garner KM, Hever MP, Freemantle SJ, Eastman A, Dmitrovsky E & Spinella MJ. (2009) High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. Cancer Res 69, 9360-9366.
10. Biswal BK, Beyrouthy MJ, Hever-Jardine MP, Armstrong D, Tomlinson CR, Christensen BC, Marsit CJ & Spinella MJ. (2012) Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS ONE 7, e53003.
11. Bokemeyer C, Oechsle K, Honecker F, Mayer F, Hartmann JT, Waller CF, Böhlke I & Kollmannsberger C. (2008) Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 19, 448-453.
12. Burger H, Nooter K, Boersma AW, Kortland CJ & Stoter G. (1997) Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int J Cancer 73, 592-599.
13. Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A & Viňals F. (2009) Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin Cancer Res 15, 3384-3395.
14. Cavallo F, Graziani G, Antinozzi C, Feldman DR, Houldsworth J, Bosl GJ, Chaganti RSK, Moynahan ME, Jasin M & Barchi M. (2012) Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. PLoS ONE 7, e51563.
15. Cavallo F, Feldman DR & Barchi M. (2013) Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors. Int J Dev Biol 57, 273-280.
16. Clavel M, Monfardini S, Fosså S, Smyth J, Renard J & Kaye SB. (1992) 5-Aza-2′-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group. Ann Oncol 3, 399-400.
17. Cleaver JE, Karplus K, Kashani-Sabet M & Limoli CL. (2001) Nucleotide excision repair "a legacy of creativity". Mutat Res 485, 23-36.
18. Di Vizio D, Cito L, Boccia A, Chieffi P, Insabato L, Pettinato G, Motti ML, Schepis F, D'Amico W, Fabiani F, Tavernise B, Venuta S, Fusco A & Viglietto G. (2005) Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. Oncogene 24, 1882-1894.
19. Douer D & Tallman MS. (2005) Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23, 2396-2410.
20. Duale N, Lindeman B, Komada M, Olsen A-K, Andreassen A, Soderlund EJ & Brunborg G. (2007) Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles. Mol Cancer 6, 53.
21. Einhorn LH, Brames MJ, Heinrich MC, Corless CL & Madani A. (2006) Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol 29, 12-13.
22. Einhorn LH, Brames MJ, Juliar B & Williams SD. (2007) Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol 25, 513-516.
23. Feldman DR, Turkula S, Ginsberg MS, Ishill N, Patil S, Carousso M, Bosl GJ & Motzer RJ. (2010) Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs 28, 523-528.
24. Feldman DR, Iyer G, Van Alstine L, Patil S, Al-Ahmadie HA, Reuter VE, Bosl GJ, Chaganti RSK & Solit DB. (2014) Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. Clin Cancer Res 20, 3712-3720.
25. Filion TM, Qiao M, Ghule PN, Mandeville M, van Wijnen AJ, Stein JL, Lian JB, Altieri DC & Stein GS. (2009) Survival responses of human embryonic stem cells to DNA damage. J Cell Physiol 220, 586-592.
26. Fizazi K, Gravis G, Flechon A, Geoffrois L, Chevreau C, Laguerre B, Delva R, Eymard JC, Rolland F, Houede N, Laplanche A, Burcoveanu D & Culine S. (2014) Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial. Ann Oncol 25, 987-991.
27. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M & Kroemer G. (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869-1883.
28. Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M & Kroemer G. (2014) Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 5, e1257.
29. Geldart TR, Gale J, McKendrick J, Kirby J & Mead G. (2006) Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure. BJU Int 98, 353-358.
30. Grande L, Bretones G, Rosa-Garrido M, Garrido-Martin EM, Hernandez T, Fraile S, Botella L, de Alava E, Vidal A, Garcia del Muro X, Villanueva A, Delgado MD & Fernandez-Luna JL. (2012) Transcription factors Sp1 and p73 control the expression of the proapoptotic protein NOXA in the response of testicular embryonal carcinoma cells to cisplatin. J Biol Chem 287, 26495-26505.
31. Gutekunst M, Oren M, Weilbacher A, Dengler MA, Markwardt C, Thomale J, Aulitzky WE & van der Kuip H. (2011) p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PLoS ONE 6, e19198.
32. Gutekunst M, Mueller T, Weilbacher A, Dengler MA, Bedke J, Kruck S, Oren M, Aulitzky WE & van der Kuip H. (2013) Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4. Cancer Res 73, 1460-1469.
33. Hinton S, Catalano P, Einhorn LH, Loehrer PJ, Kuzel T, Vaughn D & Wilding G. (2002) Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 20, 1859-1863.
34. Honecker F, Mayer F, Stoop H, Oosterhuis JW, Koch S, Bokemeyer C & Looijenga LHJ. (2003) Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors. Lab Invest 83, 1489-1495.
35. Honecker F, Wermann H, Mayer F, Gillis AJM, Stoop H, van Gurp RJLM, Oechsle K, Steyerberg E, Hartmann JT, Dinjens WNM, Oosterhuis JW, Bokemeyer C & Looijenga LHJ. (2009) Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 27, 2129-2136.
36. Honecker F, Rohlfing T, Harder S, Braig M, Gillis AJM, Glaesener S, Barett C, Bokemeyer C, Buck F, Brümmendorf TH, Looijenga LHJ & Balabanov S. (2014) Proteome analysis of the effects of all-trans retinoic acid on human germ cell tumor cell lines. J Proteomics 96, 300-313.
37. Horton JK & Wilson SH. (2013) Strategic combination of DNA-damaging agent and PARP inhibitor results in enhanced cytotoxicity. Front Oncol 3, 257.
38. Juliachs M, Vidal A, Del Muro XG, Piulats JM, Condom E, Casanovas O, Graupera M, Germà JR, Villanueva A & Viñals F. (2013) Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors. BMC Cancer 13, 382.
39. Juliachs M, Muñoz C, Moutinho CA, Vidal A, Condom E, Esteller M, Graupera M, Casanovas O, Germà JR, Villanueva A & Viñals F. (2014) The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Clin Cancer Res 20, 658-667.
40. Kälkner KM, Ullén A, Wersäll P & Cohn-Cedermark G. (2007) Temporary effect of arsenic trioxide treatment of refractory extragonadal germ cell cancer. Acta Oncol 46, 862-863.
41. Kersemaekers A-MF, Mayer F, Molier M, van Weeren PC, Oosterhuis JW, Bokemeyer C & Looijenga LHJ. (2002) Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol 20, 1551-1561.
42. Köberle B, Payne J, Grimaldi KA, Hartley JA & Masters JR. (1996) DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Biochem Pharmacol 52, 1729-1734.
43. Köberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR & Masters JR. (1997) DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 70, 551-555.
44. Köberle B, Masters JR, Hartley JA & Wood RD. (1999) Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9, 273-276.
45. Köberle B, Roginskaya V, Zima KS, Masters JRW & Wood RD. (2008) Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation. Mol Carcinog 47, 580-586.
46. Koch S, Mayer F, Honecker F, Schittenhelm M & Bokemeyer C. (2003) Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. Br J Cancer 89, 2133-2139.
47. Kollmannsberger C, Beyer J, Liersch R, Schoeffski P, Metzner B, Hartmann JT, Rick O, Stengele K, Hohloch K, Spott C, Kanz L & Bokemeyer C. (2004) Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 22, 108-114.
48. Kollmannsberger C, Honecker F & Bokemeyer C. (2008) Pharmacotherapy of relapsed metastatic testicular cancer. Expert Opin Pharmacother 9, 2259-2272.
49. Korkola JE, Houldsworth J, Bosl GJ & Chaganti RSK. (2009) Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin. BJU Int 104, 1334-1338.
50. Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, Suurmeijer AJ, Bischoff R, Gietema JA & de Jong S. (2010) Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest 120, 3594-3605.
51. Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA & de Jong S. (2011) Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway. Cell Death Dis 2, e148.
52. Koster R, van Vugt MA, Timmer-Bosscha H, Gietema JA & de Jong S. (2013) Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer. Expert Rev Mol Med 15, e12.
53. Koul S, McKiernan JM, Narayan G, Houldsworth J, Bacik J, Dobrzynski DL, Assaad AM, Mansukhani M, Reuter VE, Bosl GJ, Chaganti RS & Murty VV. (2004) Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol Cancer 3, 16.
54. Koychev D, Oechsle K, Bokemeyer C & Honecker F. (2011) Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update. Int J Androl 34, e266-e273.
55. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Ares LP, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L & der von Maase H. (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 53, 497-513.
56. Kuczyk MA, Bokemeyer C, Kollmannsberger C, Corvin S, Anastasiadis A, Machtens S, Merseburger A, Wegener G, Stenze A, Hartmann JT & Jonas U. (2004) Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience. World J Urol 22, 55-59.
57. Lipphardt ME & Albers P. (2004) Late relapse of testicular cancer. World J Urol 22, 47-54.
58. Liu L, Lian J, Zhang H, Tian H, Liang M, Yin M & Sun F. (2013) MicroRNA-302a sensitizes testicular embryonal carcinoma cells to cisplatin-induced cell death. J Cell Physiol 228, 2294-2304.
59. Loehrer PJ, Einhorn LH & Williams SD. (1986) VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 4, 528-536.
60. Loehrer PJ, Gonin R, Nichols CR, Weathers T & Einhorn LH. (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16, 2500-2504.
61. Looijenga LH, Gillis AJ, van Gurp RJ, Verkerk AJ & Oosterhuis JW. (1997) X inactivation in human testicular tumors. XIST expression and androgen receptor methylation status. Am J Pathol 151, 581-590.
62. Looijenga LHJ, Stoop H, de Leeuw HPJC, de Gouveia Brazao CA, Gillis AJM, van Roozendaal KEP, van Zoelen EJJ, Weber RFA, Wolffenbuttel KP, van Dekken H, Honecker F, Bokemeyer C, Perlman EJ, Schneider DT, Kononen J, Sauter G & Oosterhuis JW. (2003) POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 63, 2244-2250.
63. Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IGH, Berdel WE, Weissinger F, Schleicher J, Egerer G, Haas A, Schirren R, Beyer J, Bokemeyer C, Rick O & German Testicular Cancer Study Group. (2007) Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 25, 2778-2784.
64. Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T & Kollmannsberger CK. (2010) Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28, 4906-4911.
65. Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin K, Lotz J-P, Germà-Lluch JR, Powles T, Kollmannsberger C & Beyer J. (2011) Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 29, 2178-2184.
66. Mayer F, Gillis AJM, Dinjens W, Oosterhuis JW, Bokemeyer C & Looijenga LHJ. (2002) Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 62, 2758-2760.
67. Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LHJ & Bokemeyer C. (2003) Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 9, 767-773.
68. Mayer F, Wermann H, Albers P, Stoop H, Gillis AJM, Hartmann JT, Bokemeyer CC, Oosterhuis JW, Looijenga LHJ & Honecker F. (2011) Histopathological and molecular features of late relapses in non-seminomas. BJU Int 107, 936-943.
69. Mead GM & Stenning SP. (1997) The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol (R Coll Radiol) 9, 207-209.
70. Mendoza J, Martínez J, Hernández C, Pérez-Montiel D, Castro C, Fabián-Morales E, Santibáñez M, González-Barrios R, Díaz-Chávez J, Andonegui MA, Reynoso N, Oñate LF, Jiménez MA, Núñez M, Dyer R & Herrera LA. (2013) Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours. Br J Cancer 109, 68-75.
71. Moasser MM, Motzer RJ, Khoo KS, Lyn P, Murphy BA, Bosl GJ & Dmitrovsky E. (1995) all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. Cancer 76, 680-686.
72. Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, Bajorin D & Bosl GJ. (2000) Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18, 2413-2418.
73. Mueller T, Mueller LP, Luetzkendorf J, Voigt W, Simon H & Schmoll H-J. (2006) Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. Tumour Biol 27, 71-83.
74. Mueller T, Mueller LP, Holzhausen H-J, Witthuhn R, Albers P & Schmoll H-J. (2010) Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity. Histochem Cell Biol 134, 197-204.
75. Müller-Tidow C, Schwäble J, Steffen B, Tidow N, Brandt B, Becker K, Schulze-Bahr E, Halfter H, Vogt U, Metzger R, Schneider PM, Büchner T, Brandts C, Berdel WE & Serve H. (2004) High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res 10, 1241-1249.
76. Nitzsche B, Gloesenkamp C, Schrader M, Hoffmann B, Zengerling F, Balabanov S, Honecker F & Höpfner M. (2012) Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer. Br J Cancer 107, 1853-1863.
77. Noel EE, Perry J, Chaplin T, Mao X, Cazier J-B, Joel SP, Oliver RTD, Young BD & Lu Y-J. (2008) Identification of genomic changes associated with cisplatin resistance in testicular germ cell tumor cell lines. Genes Chromosom Cancer 47, 604-613.
78. Oechsle K, Kollmannsberger C, Honecker F, Mayer F, Waller CF, Hartmann JT, Boehlke I & Bokemeyer C. (2011a) Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol 60, 850-855.
79. Oechsle K, Honecker F, Cheng T, Mayer F, Czaykowski P, Winquist E, Wood L, Fenner M, Glaesener S, Hartmann JT, Chi K, Bokemeyer C & Kollmannsberger C. (2011b) Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Ann Oncol 22, 2654-2660.
80. Palmer RD, Murray MJ, Saini HK, van Dongen S, Abreu-Goodger C, Muralidhar B, Pett MR, Thornton CM, Nicholson JC, Enright AJ, Coleman N & Children's Cancer and Leukaemia Group. (2010) Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res 70, 2911-2923.
81. Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, Gaglia A, Kostopoulou V, Mylonakis N & Skarlos D. (2004) Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 15, 493-497.
82. Pedersini R, Vattemi E, Mazzoleni G & Graiff C. (2007) Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT. Lancet Oncol 8, 1039-1040.
83. Pico J-L, Rosti G, Kramar A, Wandt H, Koza V, Salvioni R, Theodore C, Lelli G, Siegert W, Horwich A, Marangolo M, Linkesch W, Pizzocaro G, Schmoll HJ, Bouzy J, Droz JP & Biron P, Genito-Urinary Group of the French Federation of Cancer Centers (GETUG-FNCLCC), France & European Group for Blood and Marrow Transplantation (EBMT). (2005) A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 16, 1152-1159.
84. Port M, Glaesener S, Ruf C, Riecke A, Bokemeyer C, Meineke V, Honecker F & Abend M. (2011) Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 10, 52.
85. Quagliana JM, O'Bryan RM, Baker L, Gottlieb J, Morrison FS, Eyre HJ, Tucker WG & Costanzi J. (1977) Phase II study of 5-azacytidine in solid tumors. Cancer Treat Rep 61, 51-54.
86. Reckova M, Mego M, Sycova-Mila Z, Obertova J, Svetlovska D & Mardiak J. (2012) Sunitinib in patients with cisplatin-refractory germ cell tumors. Onkologie 35, 455-456.
87. Rick O, Braun T, Siegert W & Beyer J. (2006) Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer 42, 1775-1779.
88. Roth BJ, Elson P, Sledge GW, Einhorn LH & Trump DL. (1993) 5-Azacytidine (NSC 102816) in refractory germ cell tumors. A phase II trial of the Eastern Cooperative Oncology Group. Invest New Drugs 11, 201-202.
89. Skotheim RI, Lind GE, Monni O, Nesland JM, Abeler VM, Fosså SD, Duale N, Brunborg G, Kallioniemi O, Andrews PW & Lothe RA. (2005) Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res 65, 5588-5598.
90. Timmer-Bosscha H, de Vries EG, Meijer C, Oosterhuis JW & Mulder NH. (1998) Differential effects of all-trans-retinoic acid, docosahexaenoic acid, and hexadecylphosphocholine on cisplatin-induced cytotoxicity and apoptosis in a cisplantin-sensitive and resistant human embryonal carcinoma cell line. Cancer Chemother Pharmacol 41, 469-476.
91. Usanova S, Piée-Staffa A, Sied U, Thomale J, Schneider A, Kaina B & Köberle B. (2010) Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 9, 248.
92. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC & Chaney SG. (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58, 3579-3585.
93. Van Echten J, van der Vloedt WS, van de Pol M, Dam A, te Meerman GJ, Schraffordt Koops H, Sleijfer DT, Oosterhuis JW & de Jong B. (1997a) Comparison of the chromosomal pattern of primary testicular nonseminomas and residual mature teratomas after chemotherapy. Cancer Genet Cytogenet 99, 59-67.
94. Van Echten J, Sleijfer DT, Wiersema J, Schraffordt Koops H, Oosterhuis JW & de Jong B. (1997b) Cytogenetics of primary testicular nonseminoma, residual mature teratoma, and growing teratoma lesion in individual patients. Cancer Genet Cytogenet 96, 1-6.
95. Velasco A, Riquelme E, Schultz M, Wistuba II, Villarroel L, Koh MS & Leach FS. (2004) Microsatellite instability and loss of heterozygosity have distinct prognostic value for testicular germ cell tumor recurrence. Cancer Biol Ther 3, 1152-1158; discussion 1159-61.
96. Velasco A, Corvalan A, Wistuba II, Riquelme E, Chuaqui R, Majerson A & Leach FS. (2008) Mismatch repair expression in testicular cancer predicts recurrence and survival. Int J Cancer 122, 1774-1777.
97. Voorhoeve PM, le Sage C, Schrier M, Gillis AJM, Stoop H, Nagel R, Liu Y-P, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH & Agami R. (2006) A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124, 1169-1181.
98. Wermann H, Stoop H, Gillis AJM, Honecker F, van Gurp RJHLM, Ammerpohl O, Richter J, Oosterhuis JW, Bokemeyer C & Looijenga LHJ. (2010) Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance. J Pathol 221, 433-442.
99. Wu Y-C, Ling T-Y, Lu S-H, Kuo H-C, Ho H-N, Yeh S-D, Shen C-N & Huang Y-H. (2012) Chemotherapeutic sensitivity of testicular germ cell tumors under hypoxic conditions is negatively regulated by SENP1-controlled sumoylation of OCT4. Cancer Res 72, 4963-4973.
100. Zhang C, Kawakami T, Okada Y & Okamoto K. (2005) Distinctive epigenetic phenotype of cancer testis antigen genes among seminomatous and nonseminomatous testicular germ-cell tumors. Genes Chromosom Cancer 43, 104-112.